Home > Healthcare > Medical Devices > Diagnostic Devices > Endobronchial Ultrasound Biopsy Device Market
Endobronchial Ultrasound Biopsy Device Market size is slated to grow considerably between 2024 and 2032, driven by the surging occurrence of lung cancer worldwide. The rising prevalence of lung cancer in Asia Pacific, particularly in nations, such as China and India, is primarily outlining the industry outlook. The high degree of indoor and outdoor air pollution across developing economies is giving rise to a number of respiratory disorders, creating a bigger patient pool that requires endobronchial ultrasound biopsy (EBUS) as a part of the treatment.
According to the World Economic Forum, in China, poor outdoor air quality leads to over 1 million deaths annually. With the rising preference for minimally invasive surgical procedures that can diagnose lung problems such as inflammation, infection, and cancer accurately, the expansion of EBUS biopsy devices is growing sharply across the globe. However, limited accessibility to advanced healthcare facilities, high equipment costs, and challenges in obtaining skilled personnel for performing procedures may restrict the industry expansion to some degree in the forthcoming period.
The growing demand for minimally invasive diagnostic procedures is driving the adoption of endobronchial ultrasound biopsy devices for accurate and efficient diagnosis of lung diseases, such as lung cancer and tuberculosis. Rising advancements in imaging technologies and probe design are enhancing the precision and diagnostic capabilities of EBUS devices and improving patient outcomes. Additionally, the increasing prevalence of respiratory disorders, coupled with rising awareness and screening programs for early detection will boost the product demand.
The integration of AI and machine learning algorithms into EBUS systems is streamlining diagnostic processes and enhancing diagnostic accuracy. The expanding application scope beyond lung diseases, such as in lymph node and mediastinal biopsies, is also broadening the industry scope.
The bronchoscopes & probes segment is anticipated to grow at a considerable CAGR between 2024 and 2032, on account of the rising transbronchial biopsy procedures being performed globally. Increasing prevalence of respiratory diseases such as bronchopulmonary hemorrhage, blockages, chronic obstructive pulmonary disease (COPD), and tumors, especially amongst the geriatric population is fueling the segment growth. As per the Asthma and Allergy Foundation of America, nearly 25 million people in the U.S. have asthma, which accounts for 1 in every 13 people.
The specialty centers end-use segment is anticipated to accumulate sizeable share of the market by 2032. Cancer treatment facilities and respiratory clinics require advanced diagnostic tools like endobronchial ultrasound biopsy devices to provide accurate and timely diagnoses for patients with lung and other respiratory conditions. The increasing incidence of lung cancer and respiratory diseases is driving the demand for such devices in specialty centers. Additionally, the availability of skilled medical professionals and advanced infrastructure are facilitating the adoption and utilization of endobronchial ultrasound biopsy devices, adding to the product application scope.
North America endobronchial ultrasound biopsy device market is projected to witness considerable growth during the forecast period. This is due to the high prevalence of respiratory diseases, such as lung cancer and tuberculosis. According to the American Cancer Society estimates, the U.S. is projected to witness 234,580 new cases of lung & bronchus cancer in 2024. The high prevalence of lung diseases will drive the demand for accurate diagnostic tools like endobronchial ultrasound biopsy devices. The presence of advanced healthcare infrastructure and skilled medical professionals in North America is also facilitating the adoption and utilization of these devices.
Some of the major endobronchial ultrasound biopsy device companies are:
Companies operating in the endobronchial ultrasound biopsy device industry are launching new biopsy devices and increasing their investments in R&D activities to come up with new innovative solutions.